Levetiracetam Hikma

Levetiracetam, the active ingredient in Levetiracetam Hikma, is an antiepileptic presented as a sterile injection for intravenous use. It is indicated for the treatment of partial seizures, generalized tonic‑clonic seizures, and myoclonic seizures, providing rapid seizure control in hospital settings.

GNH USA supplies Levetiracetam Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured products that meet EU regulatory standards through a validated cold‑chain distribution network and comprehensive post‑market support for both acute and maintenance therapy worldwide.

Levetiracetam is an antiepileptic agent used to control seizure activity in various epilepsy syndromes. - Partial seizures: reduces frequency and severity of focal onset seizures, including simple and complex partial seizures, when used as monotherapy or adjunct therapy. - Generalized tonic‑clonic seizures: helps achieve seizure freedom in patients with bilateral convulsive seizures, both as initial treatment and when added to existing regimens. - Myoclonic seizures: decreases myoclonic jerks in patients with juvenile myoclonic epilepsy and other myoclonic seizure types, improving daily functioning.

Levetiracetam may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: transient sensation of lightheadedness or imbalance. - Fatigue: generalized tiredness or reduced energy. - Headache: mild to moderate head pain. - Irritability: mood changes including increased agitation. - Nausea: occasional upset stomach or feeling of queasiness. - Somnolence: increased sleepiness or drowsiness.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or anaphylaxis requiring immediate medical attention. - Mood or behavioral changes: depression, suicidal thoughts, or aggressive behavior. - Hematologic abnormalities: rare cases of neutropenia or thrombocytopenia. - Liver enzyme elevation: abnormal liver function tests indicating possible hepatic stress. - Renal impairment: rare reports of decreased kidney function requiring monitoring.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use. - Renal function: adjust dosing in patients with impaired renal clearance. - Psychiatric history: monitor for new or worsening depression, anxiety, or suicidal thoughts. - Concomitant CNS depressants: use caution as additive sedation may occur. - Pregnancy: limited data; weigh potential benefits against unknown fetal risk. - Elderly patients: start at lower dose and titrate slowly due to increased sensitivity. - Drug interactions: review concomitant antiepileptic drugs for possible pharmacodynamic effects. - Store at ambient temperature: keep vials in original packaging, protect from light and moisture.

Levetiracetam has a relatively low interaction profile, but certain drug combinations require attention.

Major Interactions (Avoid): - Co-administration with strong enzyme inducers (e.g., carbamazepine, phenytoin) that may markedly reduce levetiracetam plasma levels.

Moderate Interactions (Monitor Closely): - Sedative agents (e.g., benzodiazepines, opioids): may increase central nervous system depression. - Other antiepileptic drugs (e.g., valproate, phenobarbital): may require dose adjustments. - Antidepressants (e.g., SSRIs): monitor for mood changes. - Immunosuppressants (e.g., cyclosporine): observe for altered drug concentrations.